<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="remains the cornerstone of clinical management for COVID-19. Prevention involves" exact="isolation" post="of suspected cases, home quarantine for the healthy, and"/>
 <result pre="management for COVID-19. Prevention involves isolation of suspected cases, home" exact="quarantine" post="for the healthy, and the use of effective Personal"/>
 <result pre="the identification of effective therapeutic agents for the prevention and" exact="treatment" post="of the disease by providing potential drug targets. This"/>
 <result pre="were observational trials while 1515 were intervention trials for the" exact="treatment" post="of COVID-19. Among these, 75 were Phase 4, 350"/>
 <result pre="Table 1 Potential therapeutic agents as repurposed drugs for the" exact="treatment" post="of COVID-19. Drug (Year of first usage) Class &amp;amp;"/>
 <result pre="and human studies Current data suggest a limited role in" exact="treatment" post="of COVID-19. [45], [46], [47] Oseltamivir(1999) Antiviral; Neuraminidase inhibitor"/>
 <result pre="No available data on its efficacy and safety for the" exact="treatment" post="of COVID-19 [34], [52], [53] Ribavirin (1986) Antiviral; Nucleoside"/>
 <result pre="Also showed antiviral activity in an animal model for SARS-CoV" exact="infection" post="Limited data available. [57], [58] Hydroxychloroquine / chloroquine (HCQ/CQ)"/>
 <result pre="of repurposed therapeutic agents that are being used for the" exact="treatment" post="of COVID-19, their class, mechanism of action, dosage, original"/>
 <result pre="are listed on clinical trial registries around the world for" exact="testing" post="the drug as a COVID-19 treatment. As Lopinavir has"/>
 <result pre="ascertain whether LPV/r may have an effective role for the" exact="treatment" post="of COVID-19 based on the available data. LPV/r has"/>
 <result pre="data. LPV/r has also been discontinued from randomization in the" exact="treatment" post="arms of the RECOVERY trial, and the SOLIDARITY trial"/>
 <result pre="Oseltamivir Oseltamivir, a neuraminidase inhibitor, is frequently prescribed for the" exact="treatment" post="of Influenza. It was prescribed to treat flu-like symptoms"/>
 <result pre="the etiologic factor. It has no scientific basis for the" exact="treatment" post="of COVID-19 as viruses of the Coronaviridae family do"/>
 <result pre="activity against SARS-CoV [50]. Eighteen studies are currently listed for" exact="testing" post="the drug on COVID-19 patients. Oseltamivir was shown to"/>
 <result pre="COVID-19 patients. Oseltamivir was shown to be ineffective in the" exact="treatment" post="of COVID-19 by an in silico assessment, which also"/>
 <result pre="polymerase (RdRp) inhibitor. It is used in China for the" exact="treatment" post="of Influenza and is capable of blocking the replication"/>
 <result pre="It is a protease inhibitor that is used for the" exact="treatment" post="of chronic pancreatitis. Camostat inhibits the host cell serine"/>
 <result pre="CQ group [61]. The authors of the study opined that" exact="treatment" post="providers should refrain from administering high doses of CQ"/>
 <result pre="the drug regimen did not have any beneficial effect on" exact="treatment" post="outcomes in COVID-19 patients, and exhibited an increased risk"/>
 <result pre="patients, and exhibited an increased risk of mortality in the" exact="treatment" post="group as compared to the control. HCQ/CQ has several"/>
 <result pre="dose use. In a recent single-center study on 2541 patients," exact="treatment" post="with HCQ alone and HCQÂ +Â Azithromycin demonstrated a"/>
 <result pre="antibody that inhibits IL-6 receptors and is used for the" exact="treatment" post="of rheumatoid arthritis and the â€œcytokine stormâ€� immune overresponse"/>
 <result pre="GI perforation and hepatotoxicity. Sixety two registered trials are currently" exact="testing" post="the safety and efficacy of Tocilizumab on COVID-19 patients."/>
 <result pre="Receptor-Inhibiting Monoclonal Antibody that has been previously used in the" exact="treatment" post="of Rheumatoid arthritis. It is currently being tested in"/>
 <result pre="a topical ointment for atopic dermatitis. Twenty trials are currently" exact="testing" post="the efficacy of the drug in COVID-19 patients. 10.2.1.4"/>
 <result pre="corticosteroid with potent anti-inflammatory properties which is prescribed for the" exact="treatment" post="of arthritis, and has potential benefit in the management"/>
 <result pre="benefits are often outweighed by the risks [74] of secondary" exact="infection" post="and delayed viral clearance. 10.3.2 Dexamethasone It is a"/>
 <result pre="glucocorticoid that has been used for several years in the" exact="treatment" post="of various inflammatory and autoimmune diseases. Preliminary results from"/>
 <result pre="support. Dexamethasone has been approved for use as a COVID-19" exact="treatment" post="in the UK [76]. As is the case with"/>
 <result pre="the infected cells. Moreover, ACE2 CAR-NK cells can competitively inhibit" exact="infection" post="of ATII cells by SARS-CoV-2 through ACE2 receptors, thereby"/>
 <result pre="particles. A multicenter, randomized Phase 1/2 trial (NCT04324996) is currently" exact="testing" post="this cell therapy. 10.4.2 RhACE2 APN01 RhACE- recombinant human"/>
 <result pre="the virus. Convalescent plasma has previously been used in the" exact="treatment" post="of viral diseases such as poliomyelitis, influenza, SARS, and"/>
 <result pre="The sheer volume of clinical trials that are investigating prospective" exact="treatment" post="options for COVID-19 emphasizes the need to expedite the"/>
 <result pre="O2 difference at baseline, 24, 48 and 168Â h after" exact="treatment" post="initiation NCT04324489 DAS181 for Severe COVID-19: Compassionate Use Experimental:"/>
 <result pre="Not Applicable Single Group Assignment;Open Label 86(â‰¥18) The incidence of" exact="treatment" post="failure in 14Â days [Â TimeÂ Frame:Â 14Â daysÂ"/>
 <result pre="for Coronavirus Disease 2019 (COVID-19) Experimental: Intervention Group Patients in" exact="treatment" post="group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3Â"/>
 <result pre="Cases and Chemoprophylaxis of Contacts as Prevention (HCQ4COV19) Experimental: Testing," exact="treatment" post="and prophylaxis of SARS-CoV-2Study 1 â€&quot; Contacts receive Hydroxychloroquine"/>
 <result pre="demographic, epidemiological and clinical and provides a swab for RT-PCR" exact="testing" post="at baseline and day 14. Contacts will be offered"/>
 <result pre="epidemiological and clinical data and provides a swab for RT-PCR" exact="testing" post="at baseline and on days 3, and 7. Cases"/>
 <result pre="days 2â€&quot;7VSActive Comparator: No Intervention- SARS-CoV-2 surveillanceIsolation of patient and" exact="contact tracing" post="as per national guidelines. Phase 3 Randomized; Open Label"/>
 <result pre="2â€&quot;7VSActive Comparator: No Intervention- SARS-CoV-2 surveillanceIsolation of patient and contact" exact="tracing" post="as per national guidelines. Phase 3 Randomized; Open Label"/>
 <result pre="6 Phase 1 Single Group Assignment;Open Label 10(â‰¥18) Plaque reduction" exact="neutralization test" post="(PNRT) [Â TimeÂ Frame:Â day 7 after first transfusionÂ"/>
 <result pre="standart critical care treatment.VSNo Intervention: Non-Plasma Therapy GroupStandart critical care" exact="treatment" post="group Not Applicable Randomized; Double blind 60(18 to 90"/>
 <result pre="trial initiated by the WHO to help find an effective" exact="treatment" post="for COVID-19 in over 100 countries. The trial will"/>
 <result pre="100 countries. The trial will assess the efficacy of four" exact="treatment" post="options against COVID-19, namely: Remdesivir; LPV/r; LPV/r with Interferon"/>
 <result pre="the European counterpart of the SOLIDARITY trial, with the same" exact="treatment" post="regimen. The study will be conducted on 3100 patients"/>
 <result pre="controlled trial of over 11,000 patients across the UK. The" exact="treatment" post="arms include LPV/r (discontinued due to lack of efficacy),"/>
 <result pre="recovered individuals for up to 12Â years [90]. Widescale serology" exact="testing" post="of recovered individuals for the identification of antibodies is"/>
 <result pre="non-pharmacological therapies such as Convalescent Plasma are currently the best" exact="treatment" post="avenues until a safe and efficacious vaccine is discovered."/>
 <result pre="remdesivir for Covid-19, https://www.clinicaltrialsarena.com/news/remdesivir-covid-19-analysis-data/. Accessed 21 July 2020. 43Gilead begins" exact="testing" post="of inhaled version of remdesivir for Covid-19, https://www.clinicaltrialsarena.com/news/gilead-inhaled-remdesivir-phasei/. Accessed"/>
 <result pre="immunodeficiency virus proteaseAntimicrob. Agents Chemother.421998321832249835517 45ChuC.M.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax59200425225614985565 46de WildeA.H.Screening"/>
 <result pre="https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery. Accessed 19 July 2020. 49WHO discontinues hydroxychloroquine and lopinavir/ritonavir" exact="treatment" post="arms for COVID-19, https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19. Accessed 19 July 2020. 50TanE.L.C.Inhibition"/>
 <result pre="COVID-19, https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19. Accessed 19 July 2020. 50TanE.L.C.Inhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugsEmerg. Infect. Dis.10200458158615200845"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect."/>
 <result pre="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 60GautretP.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt."/>
 <result pre="doi:10.1101/2020.04.07.20056424. 62MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or chloroquine with or without a macrolide for" exact="treatment" post="of COVID-19: a multinational registry analysisLancetS0140673620311806202010.1016/S0140-6736(20)31180-6 63ArshadS.Treatment with hydroxychloroquine,"/>
 <result pre="with COVID-19 in Wuhan, China: a retrospective cohort studyLancet39520201054106232171076 68PriceC.C.Tocilizumab" exact="treatment" post="for cytokine release syndrome in hospitalized COVID-19 patientsChestS0012369220316706202010.1016/j.chest.2020.06.006 69E.C."/>
 <result pre="in hospitalized COVID-19 patientsChestS0012369220316706202010.1016/j.chest.2020.06.006 69E.C. Somers, et al., Tocilizumab for" exact="treatment" post="of mechanically ventilated patients with COVID-19. 27. 70CampochiaroC.Efficacy and"/>
 <result pre="Pneumonia, https://www.globenewswire.com/news-release/2020/07/21/2064803/0/en/InflaRx-Announces-Decision-to-Enter-Phase-III-Development-of-IFX-1-in-Severe-COVID-19-Induced-Pneumonia.html. Accessed 21 July 2020. 73StockmanL.J.BellamyR.GarnerP.SARS: systematic review of" exact="treatment" post="effectsPLoS Med.32006e34316968120 74ShangL.ZhaoJ.HuY.DuR.CaoB.On the use of corticosteroids for 2019-nCoV"/>
 <result pre="report, Infect. Diseases (except HIV/AIDS), (2020). doi:10.1101/2020.06.22.20137273. 76World first coronavirus" exact="treatment" post="approved for NHS use by government, https://www.gov.uk/government/news/world-first-coronavirus-treatment-approved-for-nhs-use-by-government. Accessed 21"/>
</results>
